Retatrutide and Anxiety Effects: Evidence and Limits
A research-focused answer to "Retatrutide and Anxiety Effects: Evidence and Limits". What the evidence can establish, its limits, and retatrutide's investigational status.
FormBlends Editorial Research · Updated 2026-09-27
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Study eligibility limits the conclusion
The phase 2 obesity study enrolled 338 adults with obesity, or overweight with a weight-related condition. Enrollment rules and exclusions determine which people its findings describe. The overall result cannot establish the benefit-risk balance for every age group, diagnosis, BMI category, occupation or demographic population.
For the population or condition named in this article, check whether it was actually studied and whether the relevant outcome was prespecified. A biological connection or improvement in a laboratory marker does not prove treatment of a separate disease. A subgroup observation can also be too small or exploratory to support a clinical conclusion.
The sources here do not establish retatrutide as an approved treatment for this population or condition. Eligibility for research is determined by the individual protocol, not by a website BMI calculator or a telehealth assessment. No personalized suitability or adjustment of other treatment can be inferred from this article.
How to evaluate a claim about this topic
The question "Retatrutide and Anxiety Effects: Evidence and Limits" needs evidence that matches the actual claim. Identify the named study, the population enrolled and the outcome measured. Check whether the result was prespecified, whether there was a relevant comparator, and whether the report includes harms as well as benefits. The studies linked below provide context; they do not establish every claim implied by this question.
Sources
Does retatrutide help or worsen anxiety?
Does retatrutide make anxiety better or worse during weight loss?
- Nobody can say yet. A PubMed search pairing retatrutide or LY3437943 with anxiety, mood, depression or psychiatric terms found 15 papers: 10 on humans, 1 animal-only, and 0 randomized controlled trials. [PubMed search counts]
- The registry outcomes listed for the two phase 2 trials, 338 people with obesity and 281 with type 2 diabetes, cover body weight, BMI, waist size, HbA1c, blood glucose and drug levels. None is an anxiety measure, so those trials cannot show a change either way. [ClinicalTrials.gov NCT04881760 results]
- FDA states it has not found retatrutide safe and effective for any condition, so the anxiety report counts below come from related drugs. Anxiety appears in 1.7% of 78,023 semaglutide reports and 0.95% of 181,068 tirzepatide reports. These are shares of reports, not rates, and do not show the drugs caused anxiety. [FDA: concerns with unapproved GLP-1 drugs used for weight loss]
- A 2025 review in Nervenarzt says preliminary investigations hint at benefits of GLP-1 receptor agonists for anxiety and depression. That is an early, class-level signal, not a retatrutide result. [Nervenarzt 2025 (PubMed 40042613)]
- With so little evidence, the practical step is to tell your prescriber about any history of anxiety, and about new or worsening anxiety or mood changes during weight loss, rather than waiting to see how it goes. [PubMed search counts]
Sources: PubMed search counts, topic search with humans[mh], animals[mh] and randomized controlled trial[pt] filters (accessed 2026-11-17); ClinicalTrials.gov NCT04881760 results (accessed 2026-11-17); FDA: concerns with unapproved GLP-1 drugs used for weight loss (accessed 2026-11-17); Nervenarzt 2025 (PubMed 40042613) (accessed 2026-11-17)
Research on retatrutide and anxiety or mood
Few papers touch this question, and none is a randomized trial.
Each bar counts papers from one PubMed search; a bar says nothing about whether retatrutide helps or harms anxiety.
See the numbers
| Papers | |
|---|---|
| All papers on this topic | 15 |
| Tagged as human studies | 10 |
| Animal studies only | 1 |
| Randomized controlled trials | 0 |
PubMed search run 2026-11-17: (retatrutide OR LY3437943) AND (anxiety OR anxiety disorder OR psychiatric OR mood OR depression). Tags are added by PubMed indexers and new papers may not be tagged yet.
Source: PubMed search counts, topic search with humans[mh], animals[mh] and randomized controlled trial[pt] filters (accessed 2026-11-17)
What the papers say
No paper tests retatrutide against anxiety directly; these reviews are the closest.
- Narrative reviewNervenarzt, 2025
[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]
This 2025 German-language review covers GLP-1 drugs, including tirzepatide and retatrutide, in psychiatry. It reports preliminary signs of benefit for anxiety, depression, eating disorders and substance use. It lists nausea, vomiting and diarrhea as typical side effects.
- Literature reviewLancet Diabetes Endocrinol, 2026
Beyond weight loss: multisystem benefits of obesity medications
This 2026 Lancet Diabetes Endocrinol review covers obesity drugs, retatrutide among them, across many conditions, including depression, quality of life and food cravings. It says GLP-1-based and multiagonist therapies show beneficial effects across these conditions overall. Its abstract names depression, not anxiety, and gives no retatrutide-specific result.
- Narrative reviewCNS Drugs, 2024
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases
This 2024 CNS Drugs review on binge eating notes anxiety disorders often occur with it. It says it is unclear whether tirzepatide and retatrutide help binge eating and its comorbidities, though they have been reported to reduce binge eating in people with obesity.
Findings are summarized from each paper's abstract.
Source: PubMed, abstracts of the papers listed (accessed 2026-11-17)